Article
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Expert review of hematology - 1 Mar 2022
Arnán Sangerman Montserrat, Fernández Moreno Ainhoa, García Quintana Antonio, García-Vidal Carolina, Olave Rubio María Teresa, Del Mar Tormo Díaz María, Vendranas Meritxell, Rodriguez Macias Gabriela
Abstract excerpt
INTRODUCTION: FLT3 inhibitors have been recently introduced as novel treatment targets in patients with FLT3-mutated acute myeloid leukemia (AML). Midostaurin is an oral multikinase inhibitor that targets multiple receptor tyrosine kinases including FLT3 and has been approved for the treatment of...
Topics
- Antifungal Agents
- Antineoplastic Agents
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Staurosporine
- fms-Like Tyrosine Kinase 3
